- Home
- / G1 Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
G1 Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$7.2
2024-09-18
Market Capitalization
$377.2 M
2024-09-18
Revenue
$82.5 M
FY, 2023
CreditSafe Score
?
Score changed on Mar 25, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|
| Revenue | 45.3M | 31.5M | 51.3M | 82.5M |
| Cost of goods sold | 2.0M | 3.7M | ||
| Gross profit | 29.5M | 47.6M | ||
| Gross profit margin, % | 93.6% | 92.7% | ||
| General and administrative expense | 68.5M | 95.7M | 100.4M | 71.1M |
| Operating expense total | 141.8M | 171.9M | 183.7M | 114.8M |
| EBIT | (96.5M) | (142.5M) | (136.2M) | (39.5M) |
| EBIT margin, % | -213.0% | -452.6% | -265.4% | -47.9% |
| Interest income | 952.0K | 43.0K | 748.0K | |
| Interest expense | 1.8M | 4.7M | 10.4M | 8.8M |
| Pre tax profit | (97.8M) | (147.4M) | (145.9M) | (44.9M) |
| Income tax expense | 1.4M | 925.0K | 1.7M | 3.1M |
| Net Income | (99.3M) | (148.4M) | (147.6M) | (48.0M) |
| EPS | (2.6) | (3.5) | (3.4) | (0.9) |